Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials - PubMed (original) (raw)
Meta-Analysis
. 2017 Mar;19(3):348-355.
doi: 10.1111/dom.12825. Epub 2016 Dec 19.
Affiliations
- PMID: 27862830
- DOI: 10.1111/dom.12825
Meta-Analysis
Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials
Dandan Li et al. Diabetes Obes Metab. 2017 Mar.
Abstract
Aims: To evaluate the effects of different sodium-glucose co-transporter 2 (SGLT2) inhibitors on the risk of urinary tract infections (UTIs) and genital infections in patients with type 2 diabetes mellitus (T2DM).
Materials and methods: We systematically searched PubMed, Embase, CENTRAL, and ClinicalTrials.gov from inception to October 9, 2016 to identify randomized controlled trials (RCTs) reporting the occurrence of UTIs and genital infections in patients with T2DM treated with SGLT2 inhibitors. Pairwise and network meta-analyses were performed to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Meta-regression was performed to assess explanatory factors that might influence effect size.
Results: A total of 52 RCTs involving 36 689 patients were eligible for our meta-analysis. Canagliflozin, dapagliflozin and empagliflozin were associated with a higher risk of genital infections than placebo, with ORs ranging from 3.21 (95% CI 2.08-4.93) for dapagliflozin 2.5 mg to 5.23 (95% CI 3.86-7.09) for canagliflozin 300 mg. Only dapagliflozin 10 mg led to significantly more UTIs than placebo. The increased risk of UTIs and genital infections seemed to have a dose-response relationship for dapagliflozin only. No factors that had a significant modification effect on these infectious events were detected in meta-regression analysis.
Conclusions: The present study found that canagliflozin, dapagliflozin and empagliflozin were associated with a significantly higher risk of genital infections compared with placebo and other active treatments. Only dapagliflozin had a dose-response relationship with UTIs and genital infections.
Keywords: SGLT2 inhibitor; genital infection; network meta-analysis; type 2 diabetes; urinary tract infection.
© 2016 John Wiley & Sons Ltd.
Similar articles
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Zaccardi F, et al. Diabetes Obes Metab. 2016 Aug;18(8):783-94. doi: 10.1111/dom.12670. Epub 2016 May 13. Diabetes Obes Metab. 2016. PMID: 27059700 Review. - Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
Tang H, Li D, Zhang J, Li Y, Wang T, Zhai S, Song Y. Tang H, et al. Diabetes Obes Metab. 2017 Aug;19(8):1106-1115. doi: 10.1111/dom.12917. Epub 2017 Mar 31. Diabetes Obes Metab. 2017. PMID: 28240446 - Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Schubert A, Buchholt AT, El Khoury AC, Kamal A, Taieb V. Schubert A, et al. Curr Med Res Opin. 2017 Jun;33(6):1155-1163. doi: 10.1080/03007995.2017.1310091. Epub 2017 Apr 28. Curr Med Res Opin. 2017. PMID: 28323512 Review. - Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Tang H, Cui W, Li D, Wang T, Zhang J, Zhai S, Song Y. Tang H, et al. Diabetes Obes Metab. 2017 Jan;19(1):142-147. doi: 10.1111/dom.12785. Epub 2016 Sep 29. Diabetes Obes Metab. 2017. PMID: 27598833
Cited by
- Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus.
Gorgojo-Martínez JJ, Górriz JL, Cebrián-Cuenca A, Castro Conde A, Velasco Arribas M. Gorgojo-Martínez JJ, et al. J Clin Med. 2024 Oct 30;13(21):6509. doi: 10.3390/jcm13216509. J Clin Med. 2024. PMID: 39518647 Free PMC article. Review. - Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T.
Eleftheriadou A, Riley D, Zhao SS, Austin P, Hernández G, Lip GYH, Jackson TL, Wilding JPH, Alam U. Eleftheriadou A, et al. Diabetologia. 2024 Nov 7. doi: 10.1007/s00125-024-06314-1. Online ahead of print. Diabetologia. 2024. PMID: 39505765 No abstract available. - Increased risk of adverse events among patients with vs. without systemic autoimmune rheumatic disease prescribed sodium-glucose cotransporter 2 inhibitors: a retrospective cohort study.
Oakes EG, Ellrodt J, Guan H, Yee J, Choi MY, Costenbader KH. Oakes EG, et al. Clin Rheumatol. 2024 Oct 25. doi: 10.1007/s10067-024-07206-w. Online ahead of print. Clin Rheumatol. 2024. PMID: 39448504 - Impact of Empagliflozin on the Outcomes of β-Thalassemia Major in Patients With Type 2 Diabetes Mellitus: The THALEMPA Observational Study.
Ibraheem A, Al Tameemi WF. Ibraheem A, et al. Cureus. 2024 Sep 21;16(9):e69837. doi: 10.7759/cureus.69837. eCollection 2024 Sep. Cureus. 2024. PMID: 39435207 Free PMC article. - Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus.
Jeon JY, Kim DJ. Jeon JY, et al. Diabetes Metab J. 2024 Sep;48(5):837-846. doi: 10.4093/dmj.2024.0317. Epub 2024 Sep 12. Diabetes Metab J. 2024. PMID: 39313229 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical